Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
1 - 50 out of 224Page size: 50

Publications

  1. 2023

  2. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

    Leypoldt, L. B., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M. S., Nogai, A., Khandanpour, C., Runde, V., Jauch, A., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M. A. & Weisel, K. C., 21.09.2023, In: CANCERS. 15, 18, 4667.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Ramasamy, K., Avet-Loiseau, H., Hveding Blimark, C., Delforge, M., Gay, F., Manier, S., Martinez-Lopez, J., Mateos, M. V., Mohty, M., van de Donk, N. W. C. J. & Weisel, K., 09.2023, In: HEMASPHERE. 7, 9, p. e942

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  7. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Ludwig, H., Terpos, E., van de Donk, N., Mateos, M-V., Moreau, P., Dimopoulos, M-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M. & Sonneveld, P., 06.2023, In: LANCET ONCOL. 24, 6, p. e255-e269

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  8. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., Macro, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., Vermeulen, J., Duran, J., Borgsten, F. & Usmani, S. Z., 04.2023, In: FUTURE ONCOL. 19, 13, p. 887-895 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  9. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

    Weisel, K., Dimopoulos, M. A., San-Miguel, J., Paner, A., Engelhardt, M., Taylor, F., Lord-Bessen, J., Yip, C., Greenwood, M., Tang, J. & Cavo, M., 03.2023, In: HEMASPHERE. 7, 3, p. e843

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

    Mai, E. K., Huhn, S., Miah, K., Poos, A. M., Scheid, C., Weisel, K. C., Bertsch, U., Munder, M., Berlanga, O., Hose, D., Seckinger, A., Jauch, A., Blau, I. W., Hänel, M., Salwender, H. J., Benner, A., Raab, M. S., Goldschmidt, H. & Weinhold, N., 04.01.2023, In: BLOOD CANCER J. 13, 1, p. 1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 2023, In: J CLIN ONCOL. p. JCO2301696

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. 2022

  14. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., Abdallah, A-O., Badros, A. Z., Knop, S., Stadtmauer, E. A., Cheng, Y., Amatangelo, M., Chen, M., Nguyen, T. V., Amin, A., Peluso, T. & van de Donk, N. W. C. J., 11.2022, In: LANCET HAEMATOL. 9, 11, p. e822-e832

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M. & Cohen, Y. C., 01.10.2022, In: CL LYMPH MYELOM LEUK. 22, Suppl 2, S411.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  19. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    Weisel, K., Wadlund, A. O., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N. & Rodriguez-Otero, P., 10.2022, In: EUR J HAEMATOL. 109, 4, p. 388-397 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T-M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S. & Martin, T., 09.2022, In: CL LYMPH MYELOM LEUK. 22, 9, p. 690-701 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., Mollee, P., Kim, J. S., Shu, N., Hu, X., Li, C. & Usmani, S. Z., 09.2022, In: BRIT J HAEMATOL. 198, 6, p. 988-993 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

    Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

    Modemann, F., Ghandili, S., Schmiedel, S., Weisel, K., Bokemeyer, C. & Fiedler, W., 29.07.2022, In: CANCERS. 14, 15, 3711.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  25. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  26. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

    Schönlein, M., Wrage, V., Ghandili, S., Mellinghoff, S. C., Brehm, T. T., Leypoldt, L. B., Utz, N., Schrader, R. M., Alsdorf, W., Börschel, N., Bußmann, L., Schönrock, M., Perlick, D., Schön, G., Verpoort, K., Lütgehetmann, M., Schulze Zur Wiesch, J., Weisel, K. C., Bokemeyer, C., Schafhausen, P. & Sinn, M., 13.06.2022, In: CANCER CELL. 40, 6, p. 581-583 3 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  27. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Mateos, M-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. & Moreau, P., 05.2022, In: LEUKEMIA. 36, 5, p. 1371-1376 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

    Piechotta, V., Skoetz, N., Engelhardt, M., Einsele, H., Goldschmidt, H., Scheid, C. & guideline group, 08.04.2022, In: DTSCH ARZTEBL INT. 119, 14, p. 253-260 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  30. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

    Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Hebraud, B., Belhadj-Merzoug, K., Benboubker, L., Decaux, O., Manier, S., Caillot, D., Ukropec, J., Pei, H., Van Rampelbergh, R., Uhlar, C. M., Kobos, R. & Zweegman, S., 04.2022, In: LEUKEMIA. 36, 4, p. 1066-1077 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies

    Modemann, F., Niederwieser, C., Weisel, K., Bokemeyer, C., Fiedler, W. & Ghandili, S., 03.2022, In: LEUKEMIA LYMPHOMA. 63, 3, p. 664-671 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

    Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  33. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

    Cavo, M., San-Miguel, J. F. F., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A. A., Avet-Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V. T. D. M., Moreau, P., Mateos, M. V., Perrot, A., Iida, S., Facon, T., Kumar, S. K., van de Donk, N. W. C. J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M. & Munshi, N. C., 10.02.2022, In: BLOOD. 139, 6, p. 835-844 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

    Martin, T., Krishnan, A., Yong, K., Weisel, K., Mehra, M., Nair, S., Qi, K., Londhe, A., Diels, J., Crivera, C., Jackson, C. C., Olyslager, Y., Vogel, M., Schecter, J. M., Banerjee, A., Valluri, S., Usmani, S. Z., Berdeja, J. G. & Jagannath, S., 02.2022, In: EJHaem. 3, 1, p. 97-108 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  35. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

    Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K. C., Scheid, C., Keller, U., Hose, D. & Bassermann, F., 25.01.2022, In: BLOOD ADV. 6, 2, p. 515-520 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    Weisel, K., Martin, T., Krishnan, A., Jagannath, S., Londhe, A., Nair, S., Diels, J., Vogel, M., Schecter, J. M., Banerjee, A., Berdeja, J. G., Nesheiwat, T., Garrett, A., Qi, K., Valluri, S., Usmani, S. Z. & Yong, K., 01.2022, In: CLIN DRUG INVEST. 42, 1, p. 29-41 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

    Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., Rodriguez-Otero, P., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Beksac, M., Oriol, A., Lindsay, J., Liberati, A. M., Galli, M., Robak, P., Larocca, A., Yagci, M., Vural, F., Kanate, A. S., Jiang, R., Grote, L., Peluso, T. & Dimopoulos, M., 01.2022, In: EUR J HAEMATOL. 108, 1, p. 73-83 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

    Pape, L. J., Hambach, J., Gebhardt, A. J., Rissiek, B., Stähler, T., Tode, N., Khan, C., Weisel, K., Adam, G., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 1010270.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

    Hambach, J., Fumey, W., Stähler, T., Gebhardt, A. J., Adam, G., Weisel, K., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 838406.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  40. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

    Krohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K., Gramatzki, M., Peipp, M. & Klausz, K., 2022, In: FRONT IMMUNOL. 13, 908093.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. 2021

  42. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M-V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Schreder, M., Abildgaard, N., Hajek, R., Zojer, N., Kastritis, E., Broijl, A., Schjesvold, F., Boccadoro, M. & Terpos, E., 12.2021, In: LANCET HAEMATOL. 8, 12, p. e934-e946

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  43. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

    Siegel, D., Weisel, K., Zahlten-Kumeli, A., Medhekar, R., Ding, B. & Leleu, X., 12.2021, In: LEUKEMIA LYMPHOMA. 62, 12, p. 3002-3010 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

    Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L., 24.11.2021, In: J CLIN MED. 10, 23, 5499.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

    Ghandili, S., Weisel, K. C., Bokemeyer, C. & Leypoldt, L. B., 16.11.2021, In: ONCOL RES TREAT. 44, 12, p. 690-699 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  46. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Sborov, D., Suvannasankha, A., Weisel, K., Voorhees, P. M., Womersley, L., Baron, J., Piontek, T., Lewis, E., Opalinska, J., Gupta, I. & Cohen, A. D., 15.11.2021, In: CANCER-AM CANCER SOC. 127, 22, p. 4198-4212 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  47. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  48. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Tromp, B., Delioukina, M., Vermeulen, J. & Usmani, S. Z., 11.2021, In: LANCET ONCOL. 22, 11, p. 1582-1596 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

    Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., Fuhrmann, S., Lindemann, H-W., Weisel, K., Duerig, J. & Goldschmidt, H., 10.2021, In: LEUKEMIA. 35, 10, p. 3007-3011 5 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  50. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

    Rodriguez-Otero, P., Ayers, D., Cope, S., Davies, F. E., Delforge, M., Mojebi, A., Jansen, J. P., Weisel, K., Hege, K. & Dhanasiri, S., 10.2021, In: LEUKEMIA LYMPHOMA. 62, 10, p. 2482-2491 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  51. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

    Klein, E-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Raab, M. S., Blau, I. W., Haenel, M., Scheid, C., Goldschmidt, H. & On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg, 28.09.2021, In: CANCERS. 13, 19, p. 4856

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  52. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

    Ramasamy, K., Gay, F., Weisel, K., Zweegman, S., Mateos, M. V. & Richardson, P., 09.2021, In: Blood reviews. 49, p. 100808

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  53. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

    Davies, F., Rifkin, R., Costello, C., Morgan, G., Usmani, S., Abonour, R., Palumbo, A., Romanus, D., Hajek, R., Terpos, E., Cherepanov, D., Stull, D. M., Huang, H., Leleu, X., Berdeja, J., Lee, H. C., Weisel, K., Thompson, M., Boccadoro, M., Zonder, J., Cook, G., Puig, N., Vela-Ojeda, J., Farrelly, E., Raju, A., Blazer, M. & Chari, A., 09.2021, In: ANN HEMATOL. 100, 9, p. 2325-2337 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 3 4 5 Next